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ABSTRACT: Bone formation and remodeling involve coordinated interactions between osteoblasts and
osteoclasts through signaling networks involving a variety of molecular pathways. We hypothesized that
overexpression of Sonic hedgehog (Shh), a morphogen with a crucial role in skeletal development, would
stimulate osteoblastogenesis and bone formation in adult animals in vivo. Systemic administration of ade-
novirus expressing the N-terminal form of Shh into adult mice resulted in a primary increase in osteoblasts
and their precursors. Surprisingly, however, this was associated with altered trabecular morphology, de-
creased bone volume, and decreased compressive strength in the vertebrae. Whereas no change was detected
in the number of osteoclast precursors, bone marrow stromal cells from Shh-treated mice showed enhanced
osteoclastogenic potential in vitro. These effects were mediated by the PTH/PTH-related protein (PTHrP)
pathway as evidenced by increased sensitivity to PTH stimulation and upregulation of the PTH/PTHrP
receptor (PPR). Together, these data show that Shh has stimulatory effects on osteoprogenitors and oste-
oblasts in adult animals in vivo, which results in bone remodeling and reduced bone strength because of a
secondary increase in osteoclastogenesis.
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INTRODUCTION
T
HE COORDINATED INTERACTION of osteoblasts and oste-
oclasts is a requisite for normal bone modeling during
skeletogenesis and remodeling throughout life.
(1–3) Several
molecular pathways regulate these interactions, including
the hedgehog proteins and downstream activators such as
bone morphogenetic protein (BMP), Wnt, PTH-related
protein (PTHrP), and runt-related transcription factor 2
(Runx2).
(1–3) Many of these mechanisms have been eluci-
dated in a developmental context through the use of trans-
genic mice. However, studies of these pathways in adult
bone could promote the translation of this knowledge to
clinicalapplications,suchasthetreatmentofosteoporosisor
the enhancement of graft incorporation.
Hedgehog proteins, Sonic hedgehog (Shh), Indian
hedgehog (Ihh), and Desert hedgehog (Dhh), are secreted
morphogens that have crucial roles in embryonic pattern-
ing and the formation of a variety of organs including
the skeleton.
(4,5) For example, mice lacking Shh show
defective development of vertebrae and limbs caused by
abnormal patterning and endochondral ossiﬁcation.
(6)
Activity of Shh induces osteoblast formation from
mesenchymal stem cells through BMP
(7) and PTHrP
(8)
pathways. In addition, Shh has been shown to be involved
in early fracture repair and enhance bone defect repair in
vivo.
(9) The Ihh, secreted by osteoblasts and prehyper-
trophic chondrocytes of the growth plate, is a central reg-
ulator of endochondral bone growth through effects on
both chondrocytes and osteoblasts.
(10–15) Because signaling
through the Patched1 (Ptc1) receptor is common to Ihh
and Shh, their functions may overlap, and several studies
have used them interchangeably to elucidate various roles
in bone development.
(4)
In the context of these previous studies, we hypothe-
sized that Shh will stimulate osteoprogenitor cells and
enhance bone formation in adult animals in vivo. Our
strategy was to transiently overexpress Shh in mice using
intravenous administration of adenovirus encoding a sol-
uble N-terminal form of Shh.
(16) Our results show that,
surprisingly, overexpression of Shh alters trabecular mor-
phology leading to diminished compressive strength of the
bone. As expected, Shh treatment increases the number of
osteoblasts, osteoblast progenitors, and mesenchymal
stem cells. However, whereas the number of osteoclast
precursors are not affected, the number of osteoclasts in-
creases because of enhanced osteoclastogenic capacity of
the marrow stroma. This enhanced osteoclastogenic
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1598activity is caused, at least in part, by upregulation of the
PTH/PTHrP pathway.
MATERIALS AND METHODS
Adenovirus vectors
All adenovirus (Ad) vectors were serotype 5 and repli-
cation deﬁcient with deletions in the E1a, E1b, and E3
regions of the Ad genome. The expression cassette of
AdShhN contains the cytomegalovirus promoter/enhancer
and encodes the N-terminal portion of murine Shh with a
stop codon introduced to terminate translation immedi-
ately downstream of the glycine residue at position 198 of
the Shh peptide, allowing it to be more diffusible than
intact Shh.
(16) A vector identical to AdShhN but lacking a
cDNA coding sequence, AdNull, was used as a control.
The vectors were propagated, puriﬁed, and characterized
as previously described.
(17,18)
Experimental animals
Using an approved institutional animal committee pro-
tocol, C57BL/6 male mice 6–8 wk old (Jackson Laborato-
ries, Bar Harbor, ME, USA or Taconic, Germantown, NY,
USA) were administered AdShhN 5 3 10
10 pu in 100 ml
volume PBS, AdNull 5 3 10
10 pu, or PBS alone as controls
in the lateral tail vein and were killed 18 or 30 days later.
Levels of murine Shh were quantiﬁed using a mouse Shh
ELISA kit (R&D Systems, Minneapolis, MN, USA) in
serum collected by cardiac puncture at death (day 18).
Microscopic morphology
Isolated lumbar level 5 (L5) and L6 vertebrae that had
been dissected free of soft tissues were imaged in a mCT
scanner (MS-09 Small Specimen Scanner; GE Healthcare,
London, Canada). Images were reconstructed at 15-mm
isotropic resolution (MicroViewABA 2.2; GE Healthcare).
To measure qualities of the trabecular bone, the volume of
interest was deﬁned as the interior of each vertebral body,
excluding the cortical bone. For measurements of the
cortical bone, the volume of interest was deﬁned as the
cortical boneof the L5 vertebralbody anterior to the neural
arch, excluding the endplates. The inclusion of a standard
phantom made of SB3 (a polymer with an X-ray attenua-
tion across a wide range of voltages equivalent to bovine
cortical bone, 1.18 g of hydroxyapatite/ml) during scanning
was used for conversion of the CT attenuation values to
BMD (mg/ml). The reconstructed grayscale images were
thresholded to separate bone and marrow voxels. Using
the thresholded data, tissue volume, bone volume fraction
(bone volume/total volume), trabecular spacing, and mean
cortical thicknesswere evaluated (MicroView ABA 2.2). A
spinal segment including the L5 and L6 vertebrae from ﬁve
animals per group were evaluated in this manner.
For histology and histomorphometry, isolated spines
weredissectedofsofttissue,ﬁxedin4%paraformaldehyde,
decalciﬁed, embedded in parafﬁn, sectioned, and stained
with H&E (Histoserv, Germantown, MD, USA). Quanti-
ﬁcation of trabecular perimeter, length, and area was
accomplished using software capable of measuring histo-
morphometric parameters (Bioquant Osteo II; Nashville,
TN, USA). Data were gathered from ﬁve high-powered
ﬁelds(3200)/specimen onatleastﬁvespecimenspergroup.
Immunohistochemistry
Sections were stained with antibodies against procolla-
gen I (Developmental Studies Hybridoma Bank, Iowa
City, IA, USA), Runx2 (MBL International, Woburn, MA,
USA), or cathepsin K (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) to identify the presence of osteoblasts,
osteoblast precursors, and osteoclasts in the bone, respec-
tively. Sections were incubated overnight at 48C with a
mouse procollagen I antibody (clone SP1.D8; 1:50 dilu-
tion), a mouse Runx-2 antibody (clone 8G5; 1:50 dilution),
or a goat cathepsin K antibody (1:100 dilution) in 2% BSA
in PBS. Corresponding IgG antibodies were used as neg-
ative controls. Immunodetection was accomplished using a
biotynilated link-streptavidin kit (DAKO) or the Vectas-
tain universal Quick kit (Vector Laboratory, Burlingame,
CA, USA) and visualized with a diaminobenzidine (DAB)
chromogen detection system (DAKO) and Harris hema-
toxylin (PolyScientiﬁc, Bayshore, NY, USA) counterstain.
Quantiﬁcation of DAB
+ cells was performed on ﬁve high-
powered ﬁelds (3200)/specimen on at least ﬁve specimens
per group (Bioquant Osteo II). The osteoblast (procolla-
gen I–positive cell) and osteoclast (cathepsin K–positive
cell) number was expressed as the total number of DAB
cells and normalized to the total trabecular perimeter per
high-powered ﬁeld.
Compression testing of L6 vertebrae
Intact lumbar level 6 (L6) vertebral bodies were dis-
sected free of all soft tissues and tested to failure in com-
pression.
(19) Before testing, vertebral dimensions were
determined by measuring the height along the cranial–
caudal axis of the centrum, the width along the left–right
axis, and the depth along the dorsal–ventral axis using
calipers (±0.002 mm). Cross-sectional area was calculated
from the length and width assuming an oval geometry.
Compression tests were performed between stainless
steel platens on a servohydraulic testing system (Mini-
bionix 858; MTS Systems, Minneapolis, MN, USA). A thin
coating of cyanoacrylate adhesive was applied to the ver-
tebral endplates to prevent slipping on the platens. An
alignment pin attached to the lower platen was placed
through the dorsal nerve tube to align and orient the ver-
tebra vertically relative to the load. Compression was ap-
plied at 0.05 mm/s to a maximum load of 75 N. Ultimate
(Fu) and yield (Fy) force, compressive stiffness (EA),
displacement to failure (Du), and energy to failure were
determined. After testing, vertebrae were defatted in ac-
etone and dried at 608C for 6 h to determine dry weight and
then ashed at 6008C to determine mineral content.
(20) Ash
fraction (%) was calculated ash mass per dry mass 3 100.
Quantitative PCR
For quantitative PCR, mRNA was isolated from
bone marrow ﬂushed out from both tibias/mouse and
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was extracted using RNeasy MinElute Cleanup Kit (Invi-
trogen). Expression levels of Runx-2, PTH/PTHrP recep-
tor 1 (PPR), RANKL, and osteoprotegerin (OPG) in total
bone marrow of AdShhN-treated or control animals
(n = 3–5, all groups) were measured by TaqMan real-time
RT-PCR using primers and probes from the manufacturer
(Applied Biosystems, Foster City, CA, USA). The PCR
reactions were run in an Applied Biosystems Sequence
Detection System 7700. Relative expression levels were
calculated using the DDCt method (Applied Biosystems)
with 18sRNA as the internal control and the average of
AdNull samples as the calibrator.
Colony-forming unit ﬁbroblast, osteoblastogenesis,
and osteoclastogenesis assays
To measure the number of mesenchymal stem cells,
osteoblast precursors, and osteoclast precursors in the
bone marrow, in vitro differentiation assays were per-
formed using bone marrow cells harvested from the femurs
of AdShhN-treated and control animals (n = 5) 18 days
after vector administration. To measure the number of
mesenchymal stem cells, triplicate aliquots of 5 3 10
5
nucleated cells were plated on 35-mm dishes in Mesencult
medium (StemCell Technologies, Vancouver, British
Columbia, Canada), and colonies were counted by bright-
ﬁeld microscopy after 11 days.
(21) To quantify the number
of osteoblast progenitors in the bone marrow, triplicate
aliquots were initially plated at 5 3 10
5 cells/0.5 cm
2 in
mesenchymal stem cell sensitization media consisting of
aMEM, 20% FBS (Invitrogen, Carlsbad, CA, USA), 1%
penicillin-streptomycin (Gibco, Grand Island, NY, USA),
and 55 mM 2-mercaptoethanol (Gibco). When the cells
had grown to 70% conﬂuency, the medium was changed
to osteogenic medium consisting of aMEM, 20% FBS,
1% penicillin-streptomycin, 10 mM b-glycerophosphate
(Lonza, Alendale, NJ, USA), 200 nM dexamethasone
(Lonza), and 50 mg/ml ascorbate (Lonza). Cultures were
grown for 14 days, and the presence of osteoblasts was
conﬁrmed by staining the cultures with Alizarin red-S.
To quantify the extent of mineralization, an indicator of
osteoblastogenesis, stained cultures were incubated in
10% cetylpyridinium chloride solution (Sigma, St. Louis,
MO, USA) to release the Alizarin red-S dye, and dye
concentration was measured at an absorbance wavelength
of 570 nm. To measure the number of osteoclast precur-
sors, triplicate aliquots of 3 3 10
5 cells/ml were cultured in
media containing aMEM, 10% FBS, 1% penicillin-strep-
tomycin, and macrophage colony stimulation factor (M-
CSF, 20 ng/ml; PeproTech, Rocky Hill, NJ, USA) for 24 h.
Nonadherent cells were removed and replated at 2 3 10
5
cells/0.5 cm
2 in osteoclast differentiation medium consist-
ing of aMEM, 10% FBS, 1% penicillin-streptomycin, M-
CSF 20 ng/ml, and RANKL 100 ng/ml (R&D Systems,
Minneapolis, MN, USA). Cultures were ﬁxed on day 6 and
stained with a leukocyte acid-phosphatase/TRACP kit
(Sigma). Osteoclasts that were TRACP
+ with more than
three nuclei were counted in the entire culture at 310
magniﬁcation.
Osteoclast differentiation on stromal cell cultures
The capacity for bone marrow stromal cells (including
mesenchymal and osteoblast progenitors) to support
osteoclastogenesis was measured in co-cultures.
(22) Brieﬂy,
stromal monolayers were established as described above
in the osteoblastogenesis assay from triplicate cultures of
bone marrow cells harvested from AdShhN-treated or
control mice (n = 5). Untreated osteoclast progenitors were
isolated from naive C57BL/6 mice by cultureof whole bone
marrow in media containing aMEM, 10% FBS, 1% peni-
cillin-streptomycin, and M-CSF 20 ng/ml for 24 h. These
osteoclast precursors were added to stromal cells cultures,
and co-cultures were grown in stromal stimulation medium
containing aMEM, 20% FBS, 1% penicillin-streptomycin,
20 nM PTH(1,34) (Bachem, Torrance, CA, USA), and 20
nM 1a,25-dihydroxyvitamin D3 (Sigma). To test the role of
PTH receptor activation in co-cultures, triplicate wells
were also supplemented with vitamin D3 alone or vitamin
D3 and a PTHrP blocker, 20 nM PTH-RP(7-34) amide
(Bachem). Osteoclast number was quantiﬁed on day 6 as
described above.
RESULTS
Remodeling of vertebral trabecular bone in
mice with increased serum levels of ShhN
As expected, serum Shh levels were elevated in
AdShhN-treated animals, whose levels were 2.5 ± 1.7 ng/ml
18 days after vector administration. In contrast, serum
levels of Shh in PBS and AdNull-treated controls was be-
low the limit of detection. As shown by H&E-stained
sections of the spine by light microscopy, vertebrae of
AdShhN-treated mice showed a striking alteration in the
trabecular architecture, characterized by an increased
number of small trabeculae (Fig. 1A). Histomorphometric
analysis showed that the total trabecular perimeter in-
creased by 60% with AdShhN treatment (p < 0.0001
AdShhN versus both controls), indicating an increase in
trabecular surface area. However, this was at the expense
of trabecular area, which decreased by 70% (p < 0.0001,
AdShhN versus both controls; Fig. 1B), suggesting a de-
crease in trabecular volume. Examination of the endosteal
surfaces showed increased tortuosity. Consistent with these
ﬁndings, mCT analysis showed that tissue mineral density
was ;7% lower in the trabeculae of Shh-treated L5 (p <
0.05) and L6 (p < 0.01) vertebrae compared with both
controls (Figs. 1C and 1D; Table 1) and that bone volume
fraction was decreased by ;30% in L5 and 25% in L6
vertebrae of Shh-treated animals compared with control
(p < 0.05, AdShhN versus both controls; Table 1). Changes
in the average trabecular thickness were not detected by
mCT. However, the average separation between trabeculae
increased by ;40% in L5 and 30% in L6 vertebrae of Shh-
treated spines compared with control (p < 0.05 AdShhN
versus both controls; Table 1). Evaluation of the cortical
bone by mCT was also consistent with endosteal remodel-
ing showing that cortical thickness decreased by ;15%
and that bone volume fraction was decreased by ;10%
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AdNull for both parameters; Table 2) but that tissue
mineral density was not affected (p > 0.2, AdShhN versus
both controls; Table 2).
Decreased compressive properties in
AdShhN-treated vertebrae
To determine the functional effects of the changes in
trabecular architecture seen by histology and mCT, the
mechanical properties of L6 vertebrae were measured in
compression. Compressive stiffness was signiﬁcantly re-
duced in AdShhN-treated vertebrae (p < 0.0001 AdShhN
versus both controls) and was nearly 3-fold lower on day 18
(Fig. 2A) and nearly 4-fold lower on day 30 (Table 3)
compared with both control groups. Compressive failure
strength was also signiﬁcantly reduced in AdShhN-treated
vertebrae relative to the control groups (p < 0.0001), by
>2-fold at 18 days (Fig. 2B) and 3-fold on day 30 (Table 3),
compared with both control groups. Yield strength
was reduced with AdShhN-treatment similar to the failure
strength changes at both time points. Energy and dis-
placement to failure were not affected by treatment.
Vertebral height and depth were both signiﬁcantly de-
creased after AdShhN treatment relative to both control
groups. The mineral content and ash fraction were not
signiﬁcantly affected by AdShhN treatment (Table 3).
Coupled increases in osteoblasts and osteoclasts
in vertebrae after AdShhN treatment
To begin to examine the mechanism underlying the
changes in the trabecular architecture, the presence of ac-
tivated osteoblasts and osteoclasts was determined by im-
munohistochemistry. As expected, an ;2-fold increase in
the number of osteoblasts, positive for procollagen I, was
detected in AdShhN-treated vertebrae compared with
controls (p < 0.0001, all comparisons; Figs. 3A and 3C). At
the same time, an increase in the number of active osteo-
clasts, positive for cathepsin K, was also detected in
AdShhN (Fig. 3B). Because the magnitude of the increase
in osteoclasts was similar to that of osteoblasts (p < 0.001,
TABLE 1. Decreased Trabecular BMD in L5 and L6 AdShhN
Vertebral Bodies After Treatment With AdShhN
*
Treatment
group
Lumbar
level
Tissue
mineral
density
(mg/ml)
Bone volume
fraction
Trabecular
spacing
(mm)
PBS L5 720.8 ± 13.2 0.299 ± 0.005 0.088 ± 0.005
L6 717.1 ± 6.3 0.286 ± 0.010 0.092 ± 0.010
AdNull L5 704.1 ± 16.9 0.257 ± 0.033 0.101 ± 0.013
L6 707.9 ± 5.1 0.260 ± 0.008 0.100 ± 0.008
AdShhN L5 664.4 ± 28.8
† 0.187 ± 0.051
† 0.130 ± 0.023
‡
L6 667.8 ± 9.0
x 0.204 ± 0.020
{ 0.121 ± 0.010
**
* Parameters of BMD including tissue mineral density (mg/ml), bone
volume fraction, and trabecular separation (mm) were measured in the
trabecular bone of L5 and L6 vertebral bodies of mice 18 days after treat-
ment with AdShhN or as controls, AdNull, with no transgene or PBS using
mCT.
† p < 0.05, AdShhN vs. PBS/AdNull.
‡ p < 0.05, AdShhN vs. PBS; p > 0.3 AdShhN vs. AdNull.
x p < 0.001, AdShhN vs. PBS; p < 0.01 AdShhN vs. AdNull.
{ p < 0.01, AdShhN vs. PBS; p < 0.05 AdShhN vs. AdNull.
** p < 0.01, AdShhN vs. PBS; p < 0.05 AdShhN vs. AdNull.
TABLE 2. Decreased Cortical Bone Thickness in L5 Vertebral
Bodies After Treatment With AdShhN*
Treatment
group
Lumbar
level
Tissue
mineral
density
(mg/ml)
Bone volume
fraction
cortical
thickness
(mm)
PBS L5 930.0 ± 34.9 0.820 ± 0.037 0.0441 ± 0.003
AdNull L5 926.2 ± 6.5 0.8205 ± 0.017 0.0445 ± 0.002
AdShhN L5 907.8 ± 30.9
† 0.757 ± 0.0291
‡ 0.0382 ± 0.002
‡
* Parameters of BMD including tissue mineral density (mg/ml), bone
volume fraction, and mean cortical thickness (mm) were measured in the
anterior cortex of the L5 vertebral body of mice 18 days after treatment with
AdShhN, or as controls, AdNull, with no transgene or PBS using mCT.
† p > 0.3, AdShhN vs. PBS/AdNull.
‡ p < 0.02, AdShhN vs. PBS; p < 0.01 AdShhN vs. AdNull.
FIG. 1. Remodeling of vertebral trabecular
bone induced by elevated levels of Shh.
Vertebrae from C57BL/6 mice were har-
vested 18 days after intravenous administra-
tion of adenovirus encoding a soluble form of
Shh (AdShhN), a control adenovirus without
a transgene (AdNull), or PBS. Microscopic
morphology of mouse vertebrae were exam-
ined in histologic sections stained with H&E
by brightﬁeld microscopy or by mCT. (A)
H&E images of vertebrae. PBS (left; AdNull
(middle); and AdShhN (right). AdShhN-
treated vertebrae show remodeling of tra-
becular architecture. Bar = 200 mm. (B) Total
trabecular area in H&E-stained sagittal sec-
tions (n =5 for allgroups).(C) Reconstructed
mCT image of a 370-mm midline sagittal
section through the lumbar level 6 (L6) ver-
tebra. (D) Tissue mineral density of L6 ver-
tebrae (n = 5 for all groups). For B and D,
data shown as mean ± SE.
SONIC HEDGEHOG ALTERS TRABECULAR BONE 1601all comparisons; Fig. 3D), the ratio of osteoblasts to oste-
oclasts was not different between AdShhN and control
animals(p >0.2versusAdNull,p >0.3versusPBS;Fig.3E).
Primary increase in osteoblast precursors
and stimulation of osteoblastogenesis after
AdShhN treatment
To study further whether the primary effect of Shh
treatment was on the osteoblast precursors, osteoblasto-
genesis was examined in vivo and in vitro. A 2.5-fold
increase in the number of Runx2-positive cells in the
vertebrae of AdShhN-treated animals (p < 0.0001, all com-
parisons; Figs. 4A and 4B) showed that, in addition to the
mature, active procollagen I–positive osteoblasts (Fig. 3A),
osteoblast precursors were also increased. To conﬁrm these
ﬁndings, bone marrow cells were cultured, and in vitro as-
says were performed to measure the presence of osteoblast
precursors and of mesenchymal stem cells. A 65% increase
in the number of mineralizing nodules in AdShhN-treated
bone marrow cells conﬁrmed an increase in the number of
osteoblast precursors in those cultures (p < 0.0001; Figs. 4C
and 4D). Similarly, the colony-forming unit ﬁbroblast
(CFU-F) assay conﬁrmed a 7-fold increase in the number of
mesenchymalstemcellsinAdShhN-treatedbonemarrow(p
< 0.0001 all comparisons; Fig. 4E).
No increase in the number of osteoclast precursors
but enhanced osteoclastogenic potential of stromal
cells after AdShhN treatment
To study whether Shh also had a primary effect on os-
teoclast precursors, in vitro osteoclastogenesis assays were
performed. In contrast to the osteoblastogenesis assays,
osteoclastogenesis assays failed to show any differences
between treatment groups (p > 0.5 versus AdNull, p > 0.6
versus PBS; Figs. 5A and 5B), indicating that, whereas Shh
treatment did increase the number of osteoblast precur-
sors, it had not increased the number of osteoclast pre-
cursors. To test whether the increase in osteoclasts in vivo
was a result of Shh-induced changes to the bone marrow
stroma, co-cultures assays were performed. When bone
marrow–derived osteoclast precursors isolated from naive,
untreated animals were co-cultured on stromal cells har-
vested from AdShhN-treated animals, a 3-fold greater
number of osteoclasts were formed compared with co-
culture on stroma from AdNull- or PBS-treated controls
(p > 0.05, all comparisons; Figs. 5C and 5D; Supplemental
Figs. S1A and S1B). Together, these data suggest that the
effect on osteoclasts is secondary and is caused by en-
hanced ability of AdShhN-treated stroma to support os-
teoclastogenesis.
Because osteoclastogenesis is regulated by OPG and
RANKL molecules secreted by osteoblast precursors/
stromal cells,
(3,23,24) we determined the levels of these
molecules. As expected, RANKL gene expression was
elevated 1.5-fold in AdShhN-treated stroma (p <0 . 0 5
versus AdNull or PBS; Fig. 5E). A 5-fold increase in OPG
gene expression with Shh treatment was also in agree-
ment with our observation of increased osteoblasts (p <
0.05 versus AdNull or PBS; Fig. 5E). A 1.4-fold increase
in the OPG:RANKL ratio in Shh-treated marrow (p <
0.05; Fig. 5E) was somewhat surprising, because this
would suggest a bone-forming state rather than bone re-
sorption.
Enhanced osteoclastogenic potential of
AdShhN-treated stroma is associated with
increased activation of the PTH/PTHrP pathway
Because hedgehog signaling can have downstream ef-
fects on PTH/PTHrP signaling,
(8) and because PTH and
PTHrP are important for the growth and development
of both osteoblasts and osteoclasts,
(2,3,11,25,26) the role of
PPR activation in AdShhN-induced increase in osteoclas-
togenesis was studied. When PTH was removed from the
osteoclastogenesis media, and co-cultures stimulated with
vitamin D3 alone, AdShhN stroma still had a 4-fold greater
capacity to support osteoclastogenesis versus control
stroma (p < 0.001, all comparisons; Fig. 6A). Addition of
a PTHrP analog that blocks PPR activation abolished this
effect, conﬁrming that activation of the PTH/PTHrP
pathway was responsible for the AdShhN-induced effect
(Fig. 6A; Supplemental Fig. S1C). Whereas PTHrP ex-
pression levels were below the level detectable by quanti-
tative real-time PCR analysis, analysis of fresh bone mar-
row showed that PPR gene expression levels were
increased by >4-fold in AdShhN-treated animals (p <
0.0001 all comparisons; Fig. 6B), further supporting the
role of PPR receptor activation as the mechanism for in-
creased osteoclastogenic capacity in the AdShhN stroma.
DISCUSSION
To study the effects of Shh on osteoprogenitors and bone
formation in vivo, we overexpressed Shh in adult mice
using an adenoviral vector expressing the N-terminal form
of Shh. Our results showed that a systemic rise in serum
Shh levels increases the numbers of mesenchymal stem
cells, osteoblast precursors, and osteoblasts in the bone
marrow but results in the remodeling of trabecular bone
and reduction in bone strength caused by a secondary in-
crease in osteoclasts. The enhanced osteoclastogenesis is
FIG. 2. Decreased biomechanical properties of AdShhN-treated
vertebrae. Isolated lumbar level 6 (L6) vertebra (n = 10 vertebrae/
group)were oriented axially relativeto the loadand compressed at
0.05 mm/s to a maximum load of 75 N and then ashed after the
mechanical testing. (A) Compressive stiffness. (B) Ultimate force.
Data shown as mean ± SD.
1602 KIURU ET AL.induced by the stromal microenvironment and is mediated
in part by the PTH/PTHrP pathway, likely because of
upregulation of PPR. We conclude that Shh stimulates
osteoblastogenesis in vivo, which leads to increased re-
modeling of trabecular bone.
Osteoprogenitors and osteoclastogenesis
Remodeling is a coordinated process of bone resorption
and formation that requires the balanced interaction be-
tween osteoblastogenesis and osteoclastogenesis and is
essential for maintaining normal BMD. The osteopenic
phenotype observed in our study is nearly identical to that
very recently reported by Mak et al.
(27) and Ohba et al.
(28)
in transgenic mice with upregulated hedgehog signaling
through deletion of one copy of the hedgehog receptor,
Patched1, and it highlights, as do their studies, the impor-
tance of the osteoblast progenitor in maintaining BMD.
Our ﬁnding of a remarkably rapid and complete remod-
eling of bone resulting in highly signiﬁcant changes in the
appearance and mechanical function of the vertebrae
within 18 days attests to the importance of this pathway, not
only in development, as shown in the transgenic models, but
in postnatal bone. Furthermore, our studies provide a
compliment to that of Ohba et al.,
(28) w h or e p o r t e da ni n -
crease in BMD in postnatal mice through pharmacologic
blockade of hedgehog signaling.
Previous studies have reported on the stimulatory effects
of Shh on osteoblastogenesis and mesenchymal stem
cells.
(7–9,14,29–31) Our study, along with those using Patched1
transgenics show, however, that when stimulated in situ
by Shh, the osteoprogenitors (including marrow stromal
cells and osteoblast precursors) support osteoclastogenesis
rather than inducing bone formation.
(27,28) As expected
based on the increased osteoclastogenic capacity of Shh-
treated stroma and based on the increase in the numbers of
osteoprogenitor cells, we detected increased expression of
RANKL, a requisite molecule for osteoclast maturation
and survival that is preferentially expressed on less mature
osteoblasts and their precursors.
(32,33) However, we also
detected an increase in OPG expression, which, while
consistent with the increase in type I collagen–positive
osteoblasts induced by Shh treatment, resulted in a sur-
prising elevation of the OPG:RANKL ratio that usually
FIG. 3. Osteoblasts and osteoclasts increase
in vertebrae 18 days after AdShhN treat-
ment. (A) Immunohistochemical staining for
procollagen I, a cytoplasmic marker of oste-
oblasts: PBS (left); AdNull (middle); and
AdShhN (right). Brown indicates positive
staining. Bar = 40 mm. (B) Immunohisto-
chemical staining for cathepin K, a marker of
active osteoclasts: PBS (left); AdNull (mid-
dle); and AdShhN (right). Bar = 40 mm. (C–
E) Quantiﬁcation of osteoblast and osteo-
clast numbers (n = 5 for all groups). (C) Os-
teoblasts/mm of trabecular area. (D)
Osteoclasts/mm of trabecular area. (E) Os-
teoblast/osteoclast ratio. For C–E, data
shown as mean ± SE.
TABLE 3. Diminished Biomechanical Properties of L6 Vertebra After Treatment With AdShhN*
Treatment
group Day
Ultimate force
(N)
Yield force
(N)
Stiffness
(N/mm)
Ash fraction
(%)
PBS 18 26.897 ± 3.328 25.033 ± 4.310 78.773 ± 16.314 49.000 ± 11.770
30 30.606 ± 4.384 27.160 ± 5.773 134.528 ± 32.931 69.500 ± 9.678
AdNull 18 26.363 ± 4.561 24.580 ± 5.129 86.348 ± 36.108 48.700 ± 16.500
30 30.031 ± 2.896 28.493 ± 4.384 116.355 ± 63.630 58.750 ± 4.992
AdShhN 18 11.643 ± 3.049
† 10.358 ± 3.210
† 28.156 ± 16.220
† 45.300 ± 13.800
‡
30 9.994 ± 5.065
† 9.233 ± 4.837
† 31.614 ± 22.269
† 54.000 ± 7.874
‡
* Lumbar level 6 (L6) vertebral bodies were tested to failure in compression 18 and 30 days after treatment with AdShhN, or as controls, AdNull, with no
transgene or PBS. Biomechanical parameters including ultimate force (N), yield force (N), stiffness (N/mm), and ash fraction (%) were measured.
† p < 0.0001, AdShhN vs. PBS/AdNull.
‡ p > 0.3, AdShhN vs. PBS/AdNull.
SONIC HEDGEHOG ALTERS TRABECULAR BONE 1603declines in bone resorptive states.
(2) Several factors may
have contributed to this unexpected ﬁnding.
One possibility is that factors other than RANKL are
driving bone resorption in our model. For example, IL-6
has been reported to increase osteoclast activity with or
without enhancing the RANK-RANKL system,
(34) and
studying its expression in our model in the future might be
revealing. Another example is the potent (non-RANKL
mediated) stimulation of osteoclast activity by immature
bone matrix. Such matrix–osteoclast interactions are the-
orized to be the mechanism of decreased BMD in the
Runx2 overexpressing transgenic mouse.
(35–37) Further
study of the matrix quality in our model could show
whether such changes also occurred with Shh treatment.
FIG. 4. Immature osteoblasts, osteoblast
precursors, and mesenchymal stem cells in-
crease with AdShhN treatment. (A) Verte-
brae stained for runt-related transcription
factor-2 (Runx-2), a marker of early osteo-
blasts 18 days after treatment: PBS (left);
AdNull (middle); and AdShhN (right).
Brown indicates positive staining. Bar = 40
mm. (B) Quantiﬁcation of Runx-2–positive
cells/mm of trabecular surface area (n = 5 for
all groups). (C–E) Osteoblastogenesis and
CFU-F assays were performed using cultured
bone marrow cells from AdShhN and control
mice. Alizarin red-S staining for mineraliza-
tion after 3 wk of culture in osteogenicmedia:
PBS (left); AdNull (middle); and AdShhN
(right). Bar = 80 mm. (D) Alizarin red-S
concentration. (E) CFU-F number per well
after 14 days. For B, D, and E, data shown as
mean ± SE.
FIG. 5. No change in the number of pre-osteoclasts, but enhanced osteoclastogenic potential of bone marrow stromal cells after
AdShhN treatment. (A and B) Osteoclast precursors were harvested from bone marrow 18 days after AdShhN treatment and cultured
with osteoclast-inducing medium for 6 days. (A) Examples of osteoclast cultures stained with TRACP (PBS, left; AdNull, middle; and
AdShhN, right; bar = 100 mm) and (B) quantiﬁcation of TRACP
+ osteoclasts. Total number of TRACP
+ cells with greater than three
nuclei per cell were counted (n = 5, all groups). (C and D) Osteoclastogenesis was also measured in precursors harvested from naive mice
and co-cultured on monolayers of bone marrow stroma established from AdShhN-treated or control mice. Co-cultures were supple-
mented with dihydroxyvitamin D3 and PTH. (C) Examples of co-cultures stained with TRACP (PBS, left; AdNull, middle; and AdShhN,
right; bar = 100 mm) and (D) quantiﬁcation of osteoclasts in co-cultures. For B and D, data shown as mean ± SE. (E) Expression levels of
OPG and RANKL expression measured in RNA extracted from femoral bone marrow cells 18 days after vector administration and
quantiﬁed by TaqMan real-time PCR (n = 5, all groups). Data shown as mean ± SE.
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and Runx2 activities
(28,38,39) support the possibility that
the increase in Runx2-positive osteoblast precursors in our
study may reﬂect not only a Shh-enhanced osteoblasto-
genesis, but a direct effect of Shh on Runx2 upregulation.
To study non–RANKL-mediated factors that may stimu-
late osteoclast activity in our model is of interest for future
investigations.
Anatomical variation is another consideration. In some
studies of osteoporosis, correlations between BMD and the
OPG:RANKL ratio were found in some anatomic loca-
tions but not others.
(40,41) In this light, measuring OP-
G:RANKL in the vertebrae instead of the femurs may
have shown an tighter correlation with BMD in the ver-
tebrae. Incidentally, our studies on hematopoiesis in our
model showed the appearance of small bone islands in the
femoral diaphysis, even as the femoral metaphysic under-
went a similar decrease in BMD as the trabecular bone of
the vertebrae (M. Kiuru,C. Hidaka, R. Hubner,J. Solomon,
A. Krause, P. Leopold, R. Crystal, unpublished data, 2009).
It is possible that increased bone formation in the femoral
diaphysis may have resulted in the increased OPG:RANKL
ratio.
Additionally, it is worth noting that a decrease in the
OPG:RANKL ratio is not always found in every instance
of decreased BMD or trabecular thinning. For example,
Fazzalari et al.,
(42) found that, in osteoarthritis, the
OPG:RANKL ratio relationship was not predictive of
parameters of trabecular bone thinning. Expression of
RANKL itself, however, did correlate (inversely) with
BMD. This observation may suggest that the absolute rise
in RANKL (and its primary pro-osteoclastogenic proper-
ties) may be more important in predicting BMD than
OPG, which acts by suppressing RANKL.
PTH/PTHrP pathway activation
In addition to the increased expression of RANKL, we
found an important role for the PTH/PTHrP pathway on
osteoclastogenesis in the context of Shh treatment. Our
ﬁndings are similar to those reported by Mak et al.,
(27)
showing upregulation of PTHrP expression. Whereas we
did not detect a rise in PTHrP expression, we did ﬁnd in-
creased expression of the receptor PPR and also found that
blockade of the receptor could inhibit the increased os-
teoclastogenic capacity of Shh-treated stoma. One possi-
bility for the lack of any change in PTHrP expression levels
in our study is the short half-life and instability of PTHrP
mRNA.
(43,44) Whereas PTHrP expression levels may have
remained elevated in a transgenic mouse model, it may
have been more transient in our Ad-mediated transient
gene transfer study.
Consistent with our observations regarding the PTH/
PTHrP pathway, the increased number of osteoblasts and
osteoclasts as well as the appearance of small trabeculae in
Shh-treated mice has also been observed in transgenic mice
with constitutively activated PPR.
(45) That, in contrast to
our model, the PPR transgenic mice also showed a sub-
stantial increase in trabecular bone volume may be caused
by developmental effects that would not be expected in our
postnatal model.
Osteoprogenitors and the control of BMD
In showing the importance of osteoprogenitors in bone
remodeling, our data support the current clinical practice
of adding bone marrow cells to bone graft and suggest
furthermore that marrow cells activated with Shh or oth-
erwise enriched in early precursors may further enhance
graft remodeling and possibly graft incorporation. More
important, our model adds to the growing body of recent
literature supporting the central role of the hedgehog
pathway and of osteoblast precursors in maintaining BMD
in postnatal animals. Furthermore, our study supports
the counter-intuitive approach of judiciously suppressing
osteoblastogenesis for producing increased BMD. In ad-
dition to the study of Ohba et al.
(28) using hedgehog inhi-
bition to increase BMD, other reports of transgenic mice
with impaired osteoblastogenesis (through expression of
dominant negative Runx2 or haplo-insufﬁciency or dick-
opf-1, for example) that show increased BMD support such
a contention.
(46–48)
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